StocktoriaMoleculin Biotech, Inc. MBRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M | -$15.9M |
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M |
| Shareholders' equity | $15.0M | $11.2M | $30.9M | $52.2M | $79.0M |
| Ratios | |||||
| Return on assets | -151.7% | -153.9% | -77.9% | -50.5% | -18.9% |
| Return on equity | -223.6% | -232.4% | -96.3% | -55.6% | -20.1% |
| Current ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001659617 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.